Technical Analysis for ZLAB - Zai Lab Limited
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
24.15 | 0.12% | 0.03 |
ZLAB closed down 0.29 percent on Friday, July 20, 2018, on 69 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| See historical ZLAB trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Jul 20 | Bollinger Band Squeeze | Range Contraction | 0.12% |
| Jul 20 | Stochastic Reached Overbought | Strength | 0.12% |
| Jul 20 | Upper Bollinger Band Walk | Strength | 0.12% |
| Jul 20 | BB Squeeze + Upper Band Touch | Range Contraction | 0.12% |
| Jul 20 | Overbought Stochastic | Strength | 0.12% |
| Jul 20 | Upper Bollinger Band Touch | Strength | 0.12% |
| Jul 19 | Bollinger Band Squeeze | Range Contraction | -0.17% |
| Jul 19 | BB Squeeze + Upper Band Touch | Range Contraction | -0.17% |
| Jul 19 | Up 3 Days in a Row | Strength | -0.17% |
| Jul 19 | Up 4 Days in a Row | Strength | -0.17% |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
Zai Lab Ltd, incorporated on March 28, 2017, is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more ZLAB news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 35.74 |
| 52 Week Low | 17.85 |
| Average Volume | 90,568 |
| 200-Day Moving Average | 23.585 |
| 50-Day Moving Average | 22.8942 |
| 20-Day Moving Average | 23.472 |
| 10-Day Moving Average | 23.815 |
| Average True Range | 0.9851 |
| ADX | 11.39 |
| +DI | 15.2202 |
| -DI | 12.9511 |
| Chandelier Exit (Long, 3 ATRs ) | 21.7247 |
| Chandelier Exit (Short, 3 ATRs ) | 24.9653 |
| Upper Bollinger Band | 24.4381 |
| Lower Bollinger Band | 22.5059 |
| Percent B (%b) | 0.84 |
| BandWidth | 8.231936 |
| MACD Line | 0.3035 |
| MACD Signal Line | 0.2741 |
| MACD Histogram | 0.0293 |
| Fundamentals | Value |
|---|---|
| Market Cap | 1.18 Billion |
| Num Shares | 49.1 Million |
| EPS | -4.94 |
| Price-to-Earnings (P/E) Ratio | -4.88 |
| Price-to-Sales | 0.00 |
| Price-to-Book | 0.00 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 25.22 | ||||
| Resistance 3 (R3) | 25.22 | 24.85 | 25.03 | ||
| Resistance 2 (R2) | 24.85 | 24.57 | 24.85 | 24.97 | |
| Resistance 1 (R1) | 24.49 | 24.40 | 24.31 | 24.49 | 24.91 |
| Pivot Point | 24.12 | 24.12 | 24.03 | 24.12 | 24.12 |
| Support 1 (S1) | 23.76 | 23.84 | 23.58 | 23.76 | 23.33 |
| Support 2 (S2) | 23.39 | 23.67 | 23.39 | 23.27 | |
| Support 3 (S3) | 23.03 | 23.39 | 23.21 | ||
| Support 4 (S4) | 23.03 |
